ABIGAIL

OFFICIAL TITLE: A RANDOMIZED, 2-ARM, OPEN-LABEL, PHASE II STUDY OF ABEMACICLIB COMBINED WITH ENDOCRINE THERAPY (LETROZOLE OR FULVESTRANT) WITH OR WITHOUT A SHORT COURSE OF INDUCTION CHEMOTHERAPY WITH PACLITAXEL AS FIRST-LINE THERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-POSITIVE/HER2-NEGATIVE BREAST CANCER WITH AGGRESSIVE DISEASE CRITERIA (ABIGAIL) 

SCIENTIFIC MEETINGS

home_fondo_you_barra.jpg

SABCS 2021: - DOWNLOAD THE POSTER

home_fondo_you_barra.jpg

SPAIN

Institut Català d' Oncologia Girona (ICO)

home_fondo_you_barra.jpg

SPAIN

Hospital Universitari Sant Joan de Reus

home_fondo_you_barra.jpg

SPAIN

Complejo Asistencial Universitario de León

home_fondo_you_barra.jpg

SPAIN

Hospital Clínico Universitario de Valencia

home_fondo_you_barra.jpg

SPAIN

Hospital Clínico San Carlos

home_fondo_you_barra.jpg

SPAIN

Hospital Quirónsalud Valencia

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Miguel Servet

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario La Paz

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario de Basurto

home_fondo_you_barra.jpg

SPAIN

CO Galicia

home_fondo_you_barra.jpg

SPAIN

Complejo Hospitalario de Navarra

home_fondo_you_barra.jpg

SPAIN

Hospital Arnau de Vilanova

home_fondo_you_barra.jpg

SPAIN

Complejo Hospitalario Ruber Juan Bravo

home_fondo_you_barra.jpg

SPAIN

Hospital General Universitario de Alicante

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Clínico San Cecilio de Granada

home_fondo_you_barra.jpg

SPAIN

Consorcio Hospitalario Provincial de Castellón

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Reina Sofía

home_fondo_you_barra.jpg

SPAIN

Consorcio Hospital General Universitario de Valencia

home_fondo_you_barra.jpg

SPAIN

Fundació Althaia

home_fondo_you_barra.jpg

SPAIN

Hospital Quirónsalud Sagrado Corazón

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Arnau de Vilanova de Lleida

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Ramón y Cajal

home_fondo_you_barra.jpg

ITALY

Ospedale da Saliceto

home_fondo_you_barra.jpg

ITALY

Azienda Ospedaliero-Universitaria Cittá de la Salute e della Scienza

home_fondo_you_barra.jpg

ITALY

Ospedale San Gerardo

home_fondo_you_barra.jpg

ITALY

Istituto Europeo di Oncologia (IEO)

home_fondo_you_barra.jpg

PORTUGAL

Hospital de Santa Maria - Centro Hospitalar Lisboa Norte

home_fondo_you_barra.jpg

PORTUGAL

Hospital Fernando da Fonseca

home_fondo_you_barra.jpg

PORTUGAL

Hospital Beatriz Ângelo

home_fondo_you_barra.jpg

PORTUGAL

Hospital do Santo Antonio

CLINICAL TRIAL DETAILS

THE PRIMARY GOAL IS TO COMPARE THE EFFICACY, AS MEASURED BY 12-WEEK OVERALL RESPONSE RATE (ORR), OF ABEMACICLIB COMBINED WITH ENDOCRINE THERAPY (ET) (LETROZOLE OR FULVESTRANT) VERSUS PACLITAXEL IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-POSITIVE/HER2- NEGATIVE BREAST CANCER WITH AGGRESSIVE DISEASE CRITERIA.

 

IN ADDITION, TO EVALUATE PREDICTIVE AND/OR PROGNOSTIC AND/OR PHARMACODYNAMIC BIOMARKERS ASSOCIATED WITH DISEASE ACTIVITY STATUS OR RESPONSE TO STUDY TREATMENTS ON ARCHIVAL AND/OR FRESH TUMOR TISSUE AND BLOOD SAMPLES.

ABIGAIL AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

HR-positive/HER2-negative 

II

160

30

Spain, Portugal, Italy

Recruiting

ABIGAIL SITES

home_fondo_you_barra.jpg